Pfizer stocks - price, description, and characteristics
Pfizer Inc. is a multinational pharmaceutical company with a focus on disease prevention as well as the development of treatments and cures. The bulk of the company's income comes from the production and sale of biopharmaceutical goods. The therapeutic areas of internal medicine, cancer, hospitals, vaccines, inflammation, and immunology, as well as uncommon diseases, make up the business of Pfizer.
Charles Pfizer and Charles Erhart established Charles Pfizer & Co. in Brooklyn, New York, in 1849, which is where the business got its start.
The business grew in the late 1800s and early 1900s but remained privately owned until it first released shares of its common stock to the general public in June 1942. In the 1940s, it was the first company to mass-manufacture penicillin, and by the early 1970s, its annual revenues had surpassed $1 billion.
With a market valuation of $251.3 billion as of November 3, 2021, Pfizer has grown to be one of the largest pharmaceutical firms in the world. The Pfizer corporate office is in New York City.
The corporation that makes pharmaceuticals now has Albert Bourla as its CEO.
Pfizer works in the biotechnology and pharmaceutical sectors and is categorized as a part of the S&P 500 healthcare category.
The main rivals of Pfizer are Roche Holding AG (RHHBY), located in Switzerland, Merck & Co. Inc. (MRK), and Eli Lilly and Co. (LLY). In its fiscal year 2021, Pfizer recorded adjusted net income attributable to its common shareholders of $25.2 billion on $81.3 billion in yearly sales (FY).